Partial
Needs Revision
Patient Risk:
Medium
Summary
Several safety/label details in the AI-generated list are contradicted or not supported by the provided prescribing information, and multiple material label nuances (e.g., specific contraindication wording and pediatric indication status) are missing or incorrect.
Category Scores
Accurate Statements
WEGOVY (semaglutide) is used to treat obesity.
Supported as an indication to reduce excess body weight and maintain weight reduction long term in adults and (in injection) pediatric patients aged 12 years and older with obesity (Section 1).
WEGOVY may increase the risk of pancreatitis.
Supported: acute pancreatitis has been observed with GLP-1 receptor agonists including WEGOVY; observe patients carefully (Section 5.2).
WEGOVY may increase the risk of acute kidney injury.
Supported: postmarketing reports of acute kidney injury; monitor renal function in patients reporting adverse reactions that could lead to volume depletion (Section 5.5).
Patients taking insulin should use Wegovy with caution.
Supported in substance: hypoglycemia risk increased when used concomitantly with insulin; consider reducing dose to reduce risk of hypoglycemia (Sections 5.4 and 7.1).
Patients taking sulfonylureas should use Wegovy with caution.
Supported: hypoglycemia risk increased when used concomitantly with insulin secretagogues (e.g., sulfonylureas) (Sections 5.4 and 7.1).
Wegovy may interact with warfarin.
Not supported or addressed in the provided label excerpt (Section 7 provided does not mention warfarin).
Patients should report changes in their health or medications to their healthcare provider.
Partially supported generally via patient counseling (Section 17) to contact their healthcare provider for symptoms and management; however the specific phrasing about 'changes in ... medications' is not explicitly stated in the provided excerpt.
Unsupported Statements
Wegovy (semaglutide) is used to treat type 2 diabetes.
Not supported by the provided indication section (Section 1) which describes obesity/weight management and CV risk reduction (and MASH for injection). No type 2 diabetes indication is shown in the supplied label text.
Wegovy may increase the risk of thyroid cancer.
The provided label text warns about thyroid C-cell tumors/MTC risk rather than 'thyroid cancer' broadly; the exact claim is not supported as written.
Patients with a history of gastrointestinal disorders such as gastroparesis or inflammatory bowel disease should use Wegovy with caution.
The provided label includes a specific statement that WEGOVY is not recommended in patients with severe gastroparesis (Section 5.6). 'Inflammatory bowel disease' is not mentioned in the provided excerpt.
Wegovy may increase the risk of acute kidney injury, especially in patients with pre-existing kidney disease.
The provided excerpt does not mention increased risk specifically in pre-existing kidney disease.
Patients taking other GLP-1 receptor agonists should use Wegovy with caution.
The provided label says concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended (Section 1 Limitations of Use), but the list's phrasing ('with caution') is not supported as stated.
Wegovy may increase the risk of hypoglycemia when used with insulin, sulfonylureas, or other GLP-1 receptor agonists.
Label excerpt supports hypoglycemia risk with insulin and insulin secretagogues (e.g., sulfonylureas) (Sections 5.4, 7.1). It does not support increased hypoglycemia risk specifically with 'other GLP-1 receptor agonists'.
Wegovy is not recommended for use in patients with a history of cancer because it may increase the risk of cancer recurrence.
No such statement appears in the provided label excerpt.
Patients with a history of cardiovascular disease should use Wegovy with caution.
The CV outcomes indication includes adults with established CV disease, but 'use with caution' and the risk statement are not supported in the provided excerpt as written.
Wegovy may increase the risk of cardiovascular events.
The provided indication states reduction of major adverse CV events; the excerpt does not support an increased risk of CV events.
Wegovy is not recommended for use in pregnant women.
The provided excerpt contains pregnancy risk/benefit language and discontinuation for weight reduction when pregnancy is recognized, but does not state 'not recommended for use in pregnant women' in the provided text.
Wegovy is not recommended for use in breastfeeding women.
For WEGOVY tablets: breastfeeding not recommended during treatment (Section 8.2). For subcutaneous injection: no direct 'not recommended' statement is provided in the excerpt; thus the blanket statement is not supported across formulations.
Wegovy is not recommended for use in pregnant or breastfeeding women because it may harm the fetus or baby.
The excerpt discusses fetal risk and breastfeeding guidance, but the blanket 'not recommended' wording and causal phrasing 'may harm the fetus or baby' is not explicitly aligned to a 'not recommended' restriction in the provided text.
Patients with severe renal impairment should use Wegovy with caution.
The provided excerpt does not mention severe renal impairment use recommendations/caution (Section 8 provided does not include renal impairment specifics).
Wegovy may increase the risk of acute kidney injury in patients with severe renal impairment.
Not supported in the provided excerpt.
Wegovy may increase the risk of hypoglycemia in geriatric patients.
The provided excerpt does not state increased hypoglycemia risk in geriatric patients.
The risk of hypoglycemia in geriatric patients is especially increased when Wegovy is used with other medications that lower blood sugar.
Not supported by the provided excerpt.
Wegovy is not recommended for use in children and adolescents.
Not supported: Section 8.4 supports safety/effectiveness for pediatric patients aged 12 years and older for obesity/weight reduction; thus 'not recommended' is contrary to the provided excerpt.
The safety and efficacy of Wegovy have not been established in children and adolescents.
Not supported: safety/effectiveness have been established in pediatric patients aged 12 years and older for obesity/weight management (Section 8.4).
Wegovy may interact with clopidogrel.
Not supported by the provided excerpt (Section 7 provided does not mention clopidogrel).
Wegovy may interact with other anticoagulants.
Not supported by the provided excerpt.
Interactions with warfarin, clopidogrel, or other anticoagulants may increase the risk of bleeding.
Not supported by the provided excerpt.
Patients taking Wegovy should be monitored regularly for signs of thyroid cancer.
The provided label discusses counseling about thyroid tumor/MTC symptoms and uncertain value of routine calcitonin/ultrasound (Boxed Warning/Section 5.1). It does not support 'monitoring ... for signs of thyroid cancer' as written.
Patients taking Wegovy should be monitored regularly for other adverse effects.
The provided label includes specific monitoring for pancreatitis symptoms, renal function in certain contexts, and heart rate intervals; a general statement 'other adverse effects' is not explicitly supported.
Patients taking Wegovy should be monitored regularly for signs of pancreatitis.
The label instructs to 'observe patients carefully' after initiation and to discontinue if suspected (Section 5.2). The provided excerpt does not explicitly state 'regularly monitored' as a standing instruction.
Contradictions
High
AI Statement
Wegovy is contraindicated in patients with a history of pancreatitis.
Label Reference
Contradiction: the provided contraindications (Section 4) list personal/family history of MTC/MEN2 and prior serious hypersensitivity reaction; no pancreatitis contraindication is included.
Low
AI Statement
Wegovy is contraindicated in patients with a history of thyroid C-cell tumors.
Label Reference
Contradiction/insufficient specificity: label contraindicates personal/family history of MTC or MEN2 (Section 4 and Boxed Warning). 'History of thyroid C-cell tumors' is broader than the specific contraindication wording provided.
High
AI Statement
Wegovy may increase the risk of cardiovascular events.
Label Reference
Contradiction: Section 1 indications describe reducing the risk of major adverse CV events.
High
AI Statement
Wegovy is not recommended for use in children and adolescents.
Label Reference
Contradiction: Section 1 and Section 8.4 support use in pediatric patients aged 12 years and older with obesity for weight management.
High
AI Statement
The safety and efficacy of Wegovy have not been established in children and adolescents.
Label Reference
Contradiction: Section 8.4 states safety and effectiveness of WEGOVY injection have been established in pediatric patients aged 12 years and older for weight reduction/maintenance.
Important Omissions
For contraindications, the label specifies contraindication includes a personal or family history of MTC or MEN 2, and prior serious hypersensitivity to semaglutide or excipients (Section 4).
Importance:
Moderate
Limitations of Use: concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended (Section 1).
Importance:
Moderate
Administration/missed dose instructions and product-specific breastfeeding guidance differ between WEGOVY tablets and subcutaneous injection (Section 17 and 8.2).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Contradicted contraindications (pancreatitis) and incorrect pediatric recommendations (not recommended/efficacy not established) could lead to materially inappropriate use decisions if relied upon. Additional unsupported interaction claims (warfarin/clopidogrel) and generalized monitoring statements reduce reliability.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple high-severity contradictions to the provided label excerpt (pancreatitis contraindication; cardiovascular event risk increase; pediatric recommendations) plus unsupported interaction claims (warfarin/clopidogrel).
Suggested Improvement
Restrict statements to the supplied label wording: use the exact contraindication criteria (MTC/MEN2; hypersensitivity), align CV claims with the label’s risk-reduction indication, and correct pediatric statements to reflect established use in patients aged ≥12 years for obesity/weight management. Remove or qualify unsupported interaction and cancer/renal-geriatric hypoglycemia claims, and align monitoring language with the specific instructions provided (e.g., observe for pancreatitis signs after initiation; monitor renal function during volume-depletion-risk adverse reactions; counsel for thyroid tumor symptoms).